Alan Xu
Geschäftsführer bei Ablaze Pharmaceuticals
Aktive Positionen von Alan Xu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Ablaze Pharmaceuticals
 Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021. | Geschäftsführer | - | - |
Karriereverlauf von Alan Xu
Ausbildung von Alan Xu
| Fudan University | Undergraduate Degree |
Statistik
International
| China | 3 |
Operativ
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
| Chief Operating Officer | 1 |
Sektoral
| Consumer Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021. | Health Technology |